Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy

por Papamichael, Konstantinos, Cheifetz, Adam S
Publicado 2017

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics

por Deyhim, Tina, Cheifetz, Adam S., Papamichael, Konstantinos
Publicado 2023

Biologic Concentration Testing in Inflammatory Bowel Disease

por Vaughn, Byron P., Sandborn, William J., Cheifetz, Adam S.
Publicado 2015

A primer on common supplements and dietary measures used by patients with inflammatory bowel disease

por Minhas, Hadi J, Papamichael, Konstantinos, Cheifetz, Adam S., Gianotti, Robert J.
Publicado 2023

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis

por Feuerstein, Joseph D., Akbari, Mona, Tapper, Elliot B., Cheifetz, Adam S.
Publicado 2016

Infliximab in inflammatory bowel disease

por Papamichael, Konstantinos, Lin, Steve, Moore, Matthew, Papaioannou, Garyfallia, Sattler, Lindsey, Cheifetz, Adam S.
Publicado 2019

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

por Devlen, Jennifer, Beusterien, Kathleen, Yen, Linnette, Ahmed, Awais, Cheifetz, Adam S., Moss, Alan C.
Publicado 2014

Fr102 ASSESSING THE REPERCUSSIONS OF COVID-19 PANDEMIC ON DISEASE MANAGEMENT, PHYSICAL, AND EMOTIONAL WELL-BEING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

por El-Dallal, Mohammed, Saroufim, Ariana, Systrom, Hannah, Ballou, Sarah, Cheifetz, Adam S., Feuerstein, Joseph D.
Publicado 2021

Fr103 STRATIFYING THE IMPACT OF COVID-19 PANDEMIC ON THE EMOTIONAL AND PHYSICAL WELL-BEING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

por El-Dallal, Mohammed, Saroufim, Ariana, Systrom, Hannah, Ballou, Sarah, Cheifetz, Adam S., Feuerstein, Joseph D.
Publicado 2021

Characterization of Human CD39(+) Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease

por Longhi, Maria Serena, Moss, Alan, Bai, Aiping, Wu, Yan, Huang, Huang, Cheifetz, Adam, Quintana, Francisco J., Robson, Simon C.
Publicado 2014

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease

por Roblin, Xavier, Duru, Gérard, Papamichael, Konstantinos, Cheifetz, Adam S., Kwiatek, Sandy, Berger, Anne-Emmanuelle, Barrau, Mathilde, Waeckel, Louis, Nancey, Stephane, Paul, Stephane
Publicado 2023

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis

por Sands, Bruce E, Cheifetz, Adam S, Nduaka, Chudy I, Quirk, Daniel, Wang, Wenjin, Maller, Eric, Friedman, Gary S, Su, Chinyu, Higgins, Peter D R
Publicado 2019

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay

por Papamichael, Konstantinos, Thomas, Valerio J., Banty, Andrea, Clarke, William T., Germansky, Katharine A., Flier, Sarah N., Feuerstein, Joseph D., Melmed, Gil Y., Cheifetz, Adam S.
Publicado 2020

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient

por Nones, Rodrigo Bremer, Fleshner, Phillip R., Queiroz, Natalia Sousa Freitas, Cheifetz, Adam S., Spinelli, Antonino, Danese, Silvio, Peyrin-Biroulet, Laurent, Papamichael, Konstantinos, Kotze, Paulo Gustavo
Publicado 2021

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicent...

por Papamichael, Konstantinos, Jairath, Vipul, Zou, Guangyong, Cohen, Benjamin, Ritter, Timothy, Sands, Bruce, Siegel, Corey, Valentine, John, Smith, Michelle, Vande Casteele, Niels, Dubinsky, Marla, Cheifetz, Adam
Publicado 2022

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease

por Vaughn, Byron P., Yarur, Andres J., Graziano, Elliot, Campbell, James P., Bhattacharya, Abhik, Lee, Jennifer Y., Gheysens, Katherine, Papamichael, Konstantinos, Osterman, Mark T., Cheifetz, Adam S., Cross, Raymond K.
Publicado 2020

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative

por Edgar, Babette S, Cheifetz, Adam S, Helfgott, Simon M, Smith, Gideon P, Bandekar, Tina, Hoye-Simek, Adam, Liu, YuQian, Singh, Rubina M, Fajardo, Kristina I, Carter, Jeffrey, Simone, Laura
Publicado 2021

Validating the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease: A Novel Method for Assessing Disease Activity

por Adler, Jeremy, Colletti, Richard B, Noonan, Lenore, Berzin, Tyler M, Cheifetz, Adam S, Conklin, Laurie S, Hoops, Timothy C, Huang, Christopher S, Lewis, Blair, Mishkin, Daniel S, Hung Lo, Kim, Xiao, Yongling, Volger, Sheri
Publicado 2022

Blockade of PGK1 and ALDOA enhances bilirubin control of Th17 cells in Crohn’s disease

por Vuerich, Marta, Wang, Na, Graham, Jonathon J., Gao, Li, Zhang, Wei, Kalbasi, Ahmadreza, Zhang, Lina, Csizmadia, Eva, Hristopoulos, Jason, Ma, Yun, Kokkotou, Efi, Cheifetz, Adam S., Robson, Simon C., Longhi, Maria Serena
Publicado 2022

Endogenous antisense RNA curbs CD39 expression in Crohn’s disease

por Harshe, Rasika P., Xie, Anyan, Vuerich, Marta, Frank, Luiza Abrahão, Gromova, Barbora, Zhang, Haohai, Robles, Rene’ J., Mukherjee, Samiran, Csizmadia, Eva, Kokkotou, Efi, Cheifetz, Adam S., Moss, Alan C., Kota, Satya K., Robson, Simon C., Longhi, Maria Serena
Publicado 2020